

# Stephen J Duffy

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4558877/publications.pdf>

Version: 2024-02-01

133  
papers

3,752  
citations

201674

27  
h-index

144013

57  
g-index

134  
all docs

134  
docs citations

134  
times ranked

5233  
citing authors

#	ARTICLE	IF	CITATIONS
1	Short- and Long-Term Black Tea Consumption Reverses Endothelial Dysfunction in Patients With Coronary Artery Disease. <i>Circulation</i> , 2001, 104, 151-156.	1.6	506
2	Refractory cardiac arrest treated with mechanical CPR, hypothermia, ECMO and early reperfusion (the Tj ETQq0 0 0 rgBT /Overlock 10 T	3.6	503
3	Iron Chelation Improves Endothelial Function in Patients With Coronary Artery Disease. <i>Circulation</i> , 2001, 103, 2799-2804.	1.6	235
4	Early Experience With New Transcatheter Mitral Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2018, 71, 12-21.	2.8	229
5	Pharmacological Concentrations of Ascorbic Acid Are Required for the Beneficial Effect on Endothelial Vasomotor Function in Hypertension. <i>Hypertension</i> , 2000, 35, 936-941.	2.7	144
6	Is There an Obesity Paradox After Percutaneous Coronary Intervention in the Contemporary Era?. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 660-668.	2.9	111
7	Effects of Race and Hypertension on Flow-Mediated and Nitroglycerin-Mediated Dilatation of the Brachial Artery. <i>Hypertension</i> , 2001, 38, 1349-1354.	2.7	105
8	Effect of ascorbic acid treatment on conduit vessel endothelial dysfunction in patients with hypertension. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2001, 280, H528-H534.	3.2	104
9	Progress Towards a National Cardiac Procedure Database Development of the Australasian Society of Cardiac and Thoracic Surgeons (ASCTS) and Melbourne Interventional Group (MIG) Registries. <i>Heart Lung and Circulation</i> , 2011, 20, 10-18.	0.4	78
10	Transcatheter Aortic Valve Implantation Represents an Anti-Inflammatory Therapy Via Reduction of Shear Stress-Induced, Piezo-1-Mediated Monocyte Activation. <i>Circulation</i> , 2020, 142, 1092-1105.	1.6	70
11	Reduced UCP-1 Content in In Vitro Differentiated Beige/Brite Adipocytes Derived from Preadipocytes of Human Subcutaneous White Adipose Tissues in Obesity. <i>PLoS ONE</i> , 2014, 9, e91997.	2.5	67
12	Quality Control Activities Associated with Registries in Interventional Cardiology and Surgery. <i>Heart Lung and Circulation</i> , 2011, 20, 180-186.	0.4	64
13	Usefulness of Transient and Persistent No Reflow to Predict Adverse Clinical Outcomes Following Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2012, 109, 478-485.	1.6	57
14	Cardiovascular disease and COVID-19: Australian and New Zealand consensus statement. <i>Medical Journal of Australia</i> , 2020, 213, 182-187.	1.7	54
15	Low-Renin Hypertension With Relative Aldosterone Excess Is Associated With Impaired NO-Mediated Vasodilation. <i>Hypertension</i> , 2005, 46, 707-713.	2.7	53
16	The Establishment of the Victorian Cardiac Outcomes Registry (VCOR): Monitoring and Optimising Outcomes for Cardiac Patients in Victoria. <i>Heart Lung and Circulation</i> , 2018, 27, 451-463.	0.4	53
17	Effects of phenolics on vascular endothelial function. <i>Current Opinion in Lipidology</i> , 2003, 14, 21-27.	2.7	46
18	Feasibility and short-term efficacy of percutaneous mitral annular reduction for the therapy of functional mitral regurgitation in patients with heart failure. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 68, 205-210.	1.7	46

#	ARTICLE	IF	CITATIONS
19	Sex Disparities in Myocardial Infarction: Biology or Bias?. <i>Heart Lung and Circulation</i> , 2021, 30, 18-26.	0.4	46
20	An evaluation of octogenarians undergoing percutaneous coronary intervention from the Melbourne Interventional Group registry. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 70, 928-936.	1.7	38
21	Impact of Periprocedural Atrial Fibrillation on Short-Term Clinical Outcomes Following Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2012, 109, 471-477.	1.6	38
22	Impact of Socioeconomic Status on Clinical Outcomes in Patients With ST-Segmentâ€Elevation Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e004979.	2.2	38
23	Effects of the BET-inhibitor, RVX-208 on the HDL lipidome and glucose metabolism in individuals with prediabetes: A randomized controlled trial. <i>Metabolism: Clinical and Experimental</i> , 2016, 65, 904-914.	3.4	37
24	Matrix metalloproteinase-3 and coronary remodelling: Implications for unstable coronary disease. <i>Cardiovascular Research</i> , 2007, 75, 813-820.	3.8	36
25	The effect of intended duration of clopidogrel use on early and late mortality and major adverse cardiac events in patients with drug-eluting stents. <i>American Heart Journal</i> , 2009, 157, 899-907.	2.7	35
26	Intravascular Ultrasound Versus Angiography-Guided Drug-Eluting Stent Implantation: A Health Economic Analysis. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e006789.	2.2	34
27	Use of drugâ€Eluting stents in Victorian public hospitals. <i>Medical Journal of Australia</i> , 2006, 185, 363-367.	1.7	28
28	Pioglitazone reduces cold-induced brown fat glucose uptake despite induction of browning in cultured human adipocytes: a randomised, controlled trial in humans. <i>Diabetologia</i> , 2018, 61, 220-230.	6.3	28
29	Management of the no-reflow phenomenon. , 2011, 132, 72-85.		27
30	Impact of door-to-balloon time on long-term mortality in high- and low-risk patients with ST-elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2016, 224, 72-78.	1.7	27
31	Impact of Pre-Procedural Blood Pressure on Long-Term Outcomes Following Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2846-2855.	2.8	27
32	Utility of the <scp>ACC</scp>/<scp>AHA</scp> lesion classification as a predictor of procedural, 30â€Eday and 12â€Emonth outcomes in the contemporary percutaneous coronary intervention era. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, E227-E234.	1.7	23
33	Australian Trends in Procedural Characteristics and Outcomes in Patients Undergoing Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2018, 121, 279-288.	1.6	22
34	Prevalence and outcomes of trans-radial access for percutaneous coronary intervention in contemporary practise. <i>International Journal of Cardiology</i> , 2016, 221, 264-268.	1.7	21
35	Trends and predictors of recurrent acute coronary syndrome hospitalizations and unplanned revascularization after index acute myocardial infarction treated with percutaneous coronary intervention. <i>American Heart Journal</i> , 2019, 212, 134-143.	2.7	21
36	Sex Differences in Prehospital Delays in Patients With STâ€Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , 2021, 10, e019938.	3.7	21

#	ARTICLE	IF	CITATIONS
37	Recent trends in Australian percutaneous coronary intervention practice: insights from the Melbourne Interventional Group registry. <i>Medical Journal of Australia</i> , 2011, 195, 122-127.	1.7	18
38	Mid-term Outcomes in Patients Following Transcatheter Aortic Valve Implantation in the CoreValve Australia and New Zealand Study. <i>Heart Lung and Circulation</i> , 2015, 24, 281-290.	0.4	18
39	The prognostic significance of smoking cessation after acute coronary syndromes: an observational, multicentre study from the Melbourne interventional group registry. <i>BMJ Open</i> , 2017, 7, e016874.	1.9	18
40	Effect Of Anti-Oxidant Treatment And Cholesterol Lowering On Resting Arterial Tone, Metabolic Vasodilation And Endothelial Function In The Human Forearm: A Randomized, Placebo-Controlled Study. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2001, 28, 409-418.	1.9	17
41	Long-term survival of elderly patients undergoing percutaneous coronary intervention for myocardial infarction complicated by cardiogenic shock. <i>International Journal of Cardiology</i> , 2015, 195, 259-264.	1.7	17
42	Impact of Gender and Door-to-Balloon Times on Long-Term Mortality in Patients Presenting With ST-Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2019, 124, 833-841.	1.6	17
43	Cost-effectiveness of transcatheter aortic valve implantation compared to surgical aortic valve replacement in the intermediate surgical risk population. <i>International Journal of Cardiology</i> , 2019, 294, 17-22.	1.7	17
44	Cost-Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients With Severe Aortic Stenosis. <i>Heart Lung and Circulation</i> , 2021, 30, 547-554.	0.4	17
45	Utility of rotational atherectomy and outcomes over an eight-year period. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, 626-631.	1.7	16
46	Evolution of Australian Percutaneous Coronary Intervention (from the Melbourne Interventional) <i>TJ ETQq0 0 0 rgBT/Overlock 10 Tf 50 3</i>	1.6	16
47	Outcomes in patients with peripheral vascular disease following percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 588-597.	1.7	16
48	Agreement between coronary flow velocity reserve and stress echocardiography in intermediate-severity coronary stenoses. <i>Catheterization and Cardiovascular Interventions</i> , 2001, 53, 29-38.	1.7	14
49	Adverse impact of chronic kidney disease on clinical outcomes following percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, E801-E809.	1.7	14
50	A systematic review of cost-effectiveness of percutaneous coronary intervention vs. surgery for the treatment of multivessel coronary artery disease in the drug-eluting stent era. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2016, 2, 261-270.	4.0	13
51	Trends and Impact of Door-to-Balloon Time on Clinical Outcomes in Patients Aged <75, 75 to 84, and ≥85 Years With ST-Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2017, 120, 1245-1253.	1.6	13
52	Percutaneous Coronary Intervention Volume and Cardiac Surgery Availability Effect on Acute Coronary Syndrome-Related Cardiogenic Shock. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 876-886.	2.9	13
53	Reducing iodinated contrast volume by manipulating injection pressure during coronary angiography. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 83, 741-745.	1.7	12
54	Comparison of Outcomes of Transcatheter Aortic Valve Implantation in Patients Aged >90 Years Versus <90 Years. <i>American Journal of Cardiology</i> , 2019, 124, 1085-1090.	1.6	12

#	ARTICLE	IF	CITATIONS
55	Impact of limited English proficiency on presentation and clinical outcomes of patients undergoing primary percutaneous coronary intervention. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2020, 6, 254-262.	4.0	12
56	Effects of lignocaine vs. opioids on antiplatelet activity of ticagrelor: the LOCAL trial. <i>European Heart Journal</i> , 2021, 42, 4025-4036.	2.2	12
57	Assessment of Pretreatment With Oral P2Y12 Inhibitors and Cardiovascular and Bleeding Outcomes in Patients With Non-ST Elevation Acute Coronary Syndromes. <i>JAMA Network Open</i> , 2021, 4, e2134322.	5.9	12
58	Long-Term Outcomes Stratified by Body Mass Index in Patients Undergoing Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2020, 137, 77-82.	1.6	11
59	Impact of Gender on Transcatheter Aortic Valve Implantation Outcomes. <i>American Journal of Cardiology</i> , 2020, 133, 98-104.	1.6	11
60	Role of beta blockers following percutaneous coronary intervention for acute coronary syndrome. <i>Heart</i> , 2021, 107, 728-733.	2.9	11
61	Comparison of Long-Term Outcomes in Men versus Women Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2021, 153, 1-8.	1.6	11
62	Incidence, Predictors and Clinical Outcomes of Stent Thrombosis Following Percutaneous Coronary Intervention in Contemporary Practice. <i>Heart Lung and Circulation</i> , 2020, 29, 1433-1439.	0.4	10
63	Incidence and Predictors of Unplanned Hospital Readmission after Percutaneous Coronary Intervention. <i>Journal of Clinical Medicine</i> , 2020, 9, 3242.	2.4	10
64	Outcomes of cardiogenic shock complicating acute coronary syndromes. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E257-E267.	1.7	10
65	Compliance mismatch between stenotic and distal reference segment is associated with coronary artery disease instability. <i>Atherosclerosis</i> , 2009, 206, 179-185.	0.8	9
66	Impact of concomitant heart failure on outcomes in patients undergoing percutaneous coronary interventions: analysis of the Melbourne Interventional Group registry. <i>European Journal of Heart Failure</i> , 2011, 13, 416-422.	7.1	9
67	Incidence, Predictors and Outcomes of Major Bleeding in Patients Following Percutaneous Coronary Interventions in Australia. <i>Heart Lung and Circulation</i> , 2016, 25, 107-117.	0.4	9
68	Does the subtype of acute coronary syndrome treated by percutaneous coronary intervention predict long-term clinical outcomes?. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2018, 4, 318-327.	4.0	9
69	Prevalence, Outcomes and Cost Implications of Patients Undergoing Same Day Discharge After Elective Percutaneous Coronary Intervention in Australia. <i>Heart Lung and Circulation</i> , 2020, 29, e185-e193.	0.4	9
70	Prognostic significance of suboptimal secondary prevention pharmacotherapy after acute coronary syndromes. <i>Internal Medicine Journal</i> , 2021, 51, 366-374.	0.8	9
71	Transcatheter Versus Surgical Aortic Valve Replacement: An Updated Systematic Review and Meta-Analysis With a Focus on Outcomes by Sex. <i>Heart Lung and Circulation</i> , 2021, 30, 86-99.	0.4	9
72	Periprocedural Myocardial Injury and Coronary Artery Disease in Patients Undergoing Transcatheter Aortic Valve Replacement. <i>Cardiovascular Revascularization Medicine</i> , 2022, 35, 8-15.	0.8	9

#	ARTICLE	IF	CITATIONS
73	Comparison of Outcomes of Coronary Artery Disease Treated by Percutaneous Coronary Intervention in 3 Different Age Groups (<45, 46-65, and >65 Years). <i>American Journal of Cardiology</i> , 2021, 152, 19-26.	1.6	9
74	Temporal Trends in Patient Risk Profile and Clinical Outcomes Following Percutaneous Coronary Intervention. <i>Cardiovascular Revascularization Medicine</i> , 2021, 31, 10-16.	0.8	9
75	Thirty-day outcomes in Indigenous Australians following coronary artery bypass grafting. <i>Internal Medicine Journal</i> , 2018, 48, 780-785.	0.8	8
76	The Real-World Cost-Effectiveness of Coronary Artery Bypass Surgery Versus Stenting in High-Risk Patients: Propensity Score-Matched Analysis of a Single-Centre Experience. <i>Applied Health Economics and Health Policy</i> , 2018, 16, 661-674.	2.1	8
77	Mortality prediction after transcatheter treatment of failed bioprosthetic aortic valves utilizing various international scoring systems: Insights from the Valve-in-Valve International Data (VIVID). <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 1163-1170.	1.7	8
78	One-Year Outcomes of Patients With Established Coronary Artery Disease Presenting With Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2019, 123, 1387-1392.	1.6	8
79	Re-examining the effect of door-to-balloon delay on STEMI outcomes in the context of unmeasured confounders: a retrospective cohort study. <i>Scientific Reports</i> , 2019, 9, 19978.	3.3	8
80	Sex Differences in Radial Access for Percutaneous Coronary Intervention in Acute Coronary Syndrome Are Independent of Body Size. <i>Heart Lung and Circulation</i> , 2021, 30, 108-114.	0.4	8
81	Cardiovascular Medication Use Following Percutaneous Coronary Intervention: The Australian Experience. <i>Cardiovascular Therapeutics</i> , 2014, 32, 47-51.	2.5	7
82	Impact of renal function in patients with multi-vessel coronary disease on long-term mortality following coronary artery bypass grafting compared with percutaneous coronary intervention. <i>International Journal of Cardiology</i> , 2014, 172, 442-449.	1.7	7
83	Utility of balloon aortic valvuloplasty in the transcatheter aortic valve implantation era. <i>Open Heart</i> , 2020, 7, e001208.	2.3	7
84	Differences in outcome of percutaneous coronary intervention between Indigenous and non-Indigenous people in Victoria, Australia: a multicentre, prospective, observational, cohort study. <i>The Lancet Global Health</i> , 2021, 9, e1296-e1304.	6.3	7
85	Heart Rate as a Predictor of Outcome Following Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2018, 122, 1113-1120.	1.6	6
86	Risk-Adjusting Key Outcome Measures in a Clinical Quality PCI Registry. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1966-1975.	2.9	6
87	Trends of Use and Outcomes Associated With Glycoprotein-IIb/IIIa Inhibitors in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. <i>Annals of Pharmacotherapy</i> , 2020, 54, 414-422.	1.9	6
88	Short- and long-term outcomes of out-of-hospital cardiac arrest following ST-elevation myocardial infarction managed with percutaneous coronary intervention. <i>Resuscitation</i> , 2020, 150, 121-129.	3.0	6
89	Incidence and risk factors for stroke following percutaneous coronary intervention. <i>International Journal of Stroke</i> , 2020, 15, 909-922.	5.9	6
90	Preoperative biomarker evaluation for the prediction of cardiovascular events after major vascular surgery. <i>Journal of Vascular Surgery</i> , 2019, 70, 1564-1575.	1.1	5

#	ARTICLE	IF	CITATIONS
91	Relation of Preprocedure Platelet-to-Lymphocyte Ratio and Major Adverse Cardiovascular Events Following Transcatheter Aortic Valve Implantation for Aortic Stenosis. <i>American Journal of Cardiology</i> , 2022, 163, 65-70.	1.6	5
92	Determinants of Undertaking Coronary Angiography and Adverse Prognostic Predictors Among Patients Presenting With Out-of-Hospital Cardiac Arrest and a Shockable Rhythm. <i>American Journal of Cardiology</i> , 2022, 171, 75-83.	1.6	5
93	Does Statin Benefits Patients with Heart Failure Undergoing Percutaneous Coronary Intervention? Findings from the Melbourne Interventional Group Registry. <i>Cardiovascular Drugs and Therapy</i> , 2018, 32, 57-64.	2.6	4
94	Outcomes of Percutaneous Coronary Intervention in Patients With Rheumatoid Arthritis. <i>American Journal of Cardiology</i> , 2021, 140, 39-46.	1.6	4
95	Sex disparity in secondary prevention pharmacotherapy and clinical outcomes following acute coronary syndrome. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2022, 8, 420-428.	4.0	4
96	Comparison of Long-Term Outcomes After Percutaneous Coronary Intervention in Patients With Insulin-Treated Versus Non-Insulin Treated Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2021, 148, 36-43.	1.6	4
97	Novel cardiac therapies and innocent bystanders. <i>Lancet, The</i> , 2008, 371, 1726-1728.	13.7	3
98	Delays in primary percutaneous coronary treatment for patients with STâ€elevation myocardial infarction. <i>Medical Journal of Australia</i> , 2018, 209, 130-131.	1.7	3
99	Factors That Prevent Progression to Transcatheter Aortic Valve Implantation (TAVI). <i>Heart Lung and Circulation</i> , 2019, 28, 1225-1234.	0.4	3
100	The Impact of Out-of-Hours Presentation on Clinical Outcomes in ST-Elevation Myocardial Infarction. <i>Heart Lung and Circulation</i> , 2020, 29, 814-823.	0.4	3
101	Impact of lunar phase on outcomes following STâ€elevation myocardial infarction. <i>Internal Medicine Journal</i> , 2020, 50, 322-329.	0.8	3
102	The cost-effectiveness of guideline-driven use of drug-eluting stents: propensity-score matched analysis of a seven-year multicentre experience. <i>Current Medical Research and Opinion</i> , 2020, 36, 419-426.	1.9	3
103	Long-term outcomes following percutaneous coronary intervention to an unprotected left main coronary artery in cardiogenic shock. <i>International Journal of Cardiology</i> , 2020, 308, 20-25.	1.7	3
104	Short- and Long-Term Outcomes After Transcatheter Aortic Valve Implantation in Public and Private Hospital Settings: A Propensity-Matched Analysis. <i>Heart Lung and Circulation</i> , 2021, 30, 1910-1917.	0.4	3
105	Totally Occluded Culprit Coronary Artery in Patients with Non-ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2021, 156, 52-57.	1.6	3
106	The role of CHA2DS2-VASc score in evaluating patients with atrial fibrillation undergoing percutaneous coronary intervention. <i>Coronary Artery Disease</i> , 2021, 32, 288-294.	0.7	3
107	Reperfusion Times and Outcomes in Patients With ST-Elevation Myocardial Infarction Presenting Without Pre-Hospital Notification. <i>Cardiovascular Revascularization Medicine</i> , 2022, 41, 136-141.	0.8	3
108	Sex differences in treatment and outcomes of patients with inâ€ehospital STâ€elevation myocardial infarction. <i>Clinical Cardiology</i> , 2022, 45, 427-434.	1.8	3

#	ARTICLE	IF	CITATIONS
109	Predictors and Outcomes of the No-Reflow Phenomenon. <i>Heart Lung and Circulation</i> , 2008, 17, S176.	0.4	2
110	Device-Based Therapy in the Prevention of Contrast-Induced Nephropathy. <i>Interventional Cardiology Clinics</i> , 2014, 3, 421-428.	0.4	2
111	Myopericarditis with preserved left ventricular function secondary to <i>Neisseria meningitidis</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 92, 241-244.	1.8	2
112	Clinical outcomes following ST-elevation myocardial infarction secondary to stent thrombosis treated by percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E406-E415.	1.7	2
113	Comparison of Long-Term Mortality in Patients With Single Coronary Narrowing and Diabetes Mellitus to That of Patients With Multivessel Coronary Narrowing Without Diabetes Mellitus. <i>American Journal of Cardiology</i> , 2021, 142, 1-4.	1.6	2
114	Rescue PCI in the management of STEMI: Contemporary results from the Melbourne Interventional Group registry. <i>IJC Heart and Vasculature</i> , 2021, 33, 100745.	1.1	2
115	Characteristics and outcomes of unsuccessful percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2021, , .	1.7	2
116	Relation of Timing of Percutaneous Coronary Intervention on Outcomes in Patients With Non-ST Segment Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2020, 136, 15-23.	1.6	2
117	Long-term mortality in asymptomatic patients with stable ischemic heart disease undergoing percutaneous coronary intervention. <i>American Heart Journal</i> , 2022, 244, 77-85.	2.7	2
118	Role of renin-angiotensin system antagonists on long-term mortality post-percutaneous coronary intervention in reduced and preserved ejection fraction. <i>Clinical Research in Cardiology</i> , 2022, , 1.	3.3	2
119	Adverse 30-Day Clinical Outcomes and Long-Term Mortality Among Patients With Preprocedural Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>Heart Lung and Circulation</i> , 2022, , .	0.4	2
120	Differences in outcomes of patients with in-hospital versus out-of-hospital ST-elevation myocardial infarction: a registry analysis. <i>BMJ Open</i> , 2022, 12, e052000.	1.9	2
121	Trends and Clinical Outcomes in Patients Undergoing Primary Percutaneous Revascularisation for ST-Elevation Myocardial Infarction: A Single Centre Experience. <i>Heart Lung and Circulation</i> , 2018, 27, 683-692.	0.4	1
122	Transcatheter Mitral Valve Implantation with the Medtronic Intrepid <sup>®</sup> Transcatheter Mitral Valve Replacement System. <i>Future Cardiology</i> , 2019, 15, 281-293.	1.2	1
123	Impact of Age and Sex on Treatment and Outcomes Following Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1934-1936.	2.8	1
124	Outcomes of Thrombus Aspiration During Primary Percutaneous Coronary Intervention for <sc>ST-elevation</sc> Myocardial Infarction. <i>Internal Medicine Journal</i> , 0, , .	0.8	1
125	Reply to the letter. <i>Catheterization and Cardiovascular Interventions</i> , 2002, 55, 272-273.	1.7	0
126	Temporal Changes in Characteristics, Treatment and Outcomes of Heart Failure Patients Undergoing Percutaneous Coronary Intervention Findings From Melbourne Interventional Group Registry. <i>Heart Lung and Circulation</i> , 2019, 28, 1018-1026.	0.4	0



#	ARTICLE	IF	CITATIONS
127	Reply. Journal of the American College of Cardiology, 2019, 74, 2012-2013.	2.8	0
128	Medium-Term Bioresorbable Scaffold Outcomes Utilising Data From an Australian Clinical Quality Registry. Heart Lung and Circulation, 2020, 29, 1440-1448.	0.4	0
129	Clinical Outcomes in Older Patients Undergoing Percutaneous Coronary Intervention for Non-ST-Elevation Acute Coronary Syndromes. Heart Lung and Circulation, 2021, 30, 275-281.	0.4	0
130	Difference in a decade: percutaneous coronary interventions in Australia. Internal Medicine Journal, 2021, 51, 138-139.	0.8	0
131	Health-related quality of life following percutaneous coronary intervention during the COVID-19 pandemic. Quality of Life Research, 2022, , 1.	3.1	0
132	Sex differences in prehospital analgesia in patients presenting with acute coronary syndromes and their association with clinical outcomes. Catheterization and Cardiovascular Interventions, 2022, , .	1.7	0
133	Sex-Specific Outcomes Following Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting for Left Main Disease: A Systematic Review and Meta-Analysis. Heart Lung and Circulation, 2022, , .	0.4	0